Clinical significance of microRNA-155 expression in hepatocellular carcinoma

Guan,Chengnong; Yang,Feng; He,Xichun; Li,Tuhua; Yang,Qingmei; He,Huiping; Xu,Meng

doi:10.3892/ol.2015.4048

Clinical significance of microRNA-155 expression in hepatocellular carcinoma

Authors:
- Chengnong Guan
- Feng Yang
- Xichun He
- Tuhua Li
- Qingmei Yang
- Huiping He
- Meng Xu
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong 510630, P.R. China, Center of Oncology, The Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong 524000, P.R. China
Published online on: December 22, 2015 https://doi.org/10.3892/ol.2015.4048
Pages: 1574-1580

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to evaluate the expression of microRNA-155 (miR-155) in hepatocellular carcinoma (HCC) and adjacent normal tissues, and assess its correlation with clinicopathological characteristics of this tumor type. miR‑155 expression was detected in 40 HCC tissue samples and 40 samples of adjacent tumor‑free tissue using fluorescent reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR). The association between miR‑155 expression, clinicopathological features and 1‑year relapse‑free survival (RFS) in HCC and adjacent normal tissue samples was analyzed. RT‑qPCR results revealed that, in 25 cases (62.5%), miR‑155 expression levels were significantly increased in HCC tissues compared with the expression levels observed in pericarcinomatous tissues (P<0.05). miR‑155 expression was observed to be significantly correlated with vessel invasion, Edmonson classification and clinical stage (P<0.05). However, miR‑155 expression was not significantly correlated with gender, age, tumor size, tumor number, hepatitis B virus DNA copy number, cirrhosis or concentration of α‑fetoprotein (P>0.05). A positive correlation was observed between late TNM classification of malignant tumor stage and 1‑year RFS (P<0.05). Patients exhibiting high miR‑155 expression levels were observed to exhibit a lower 1‑year RFS than that of patients with reduced expression of miR‑155 (48 vs. 73.3%), however this difference was not statistically significant (P=0.105). Additionally, correlations were observed between miR‑155 expression and reduced differentiation, increased invasiveness and late stages of HCC. The current results demonstrated that miR‑155 may be involved in the tumorigenesis of HCC and may be associated with clinical characteristics of HCC patients. Additional studies are required to clarify the mechanism of miR-155.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Shin HR, Bray F, et al: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
3	Lencioni R, Chen XP, Dagher L and Venook AP: Treatment of intermediate/advanced hepatocellular carcinoma in the clinic, How can outcomes be improved? Oncologist. 15((Suppl 4)): S42–S52. 2010. View Article : Google Scholar
4	Suh SJ and Yim HJ: Current status of molecular targeted therapies in hepatocellular carcinoma. Korean J Gastroenterol. 61:136–146. 2013.(In Korean). View Article : Google Scholar : PubMed/NCBI
5	Qin S: Primary Liver Cancer Diagnosis and Treatment Expert Panel of the Chinese Ministry of Health: Guidelines on the diagnosis and treatment of primary liver cancer (2011 edition). Chin Clin Oncol. 1:102012.PubMed/NCBI
6	Sanyal AJ, Yoon SK and Lencioni R: The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist. 15(Suppl 4): 14–22. 2010. View Article : Google Scholar : PubMed/NCBI
7	Kumar M, Zhao X and Wang XW: Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma, One step closer to personalized medicine? Cell Biosci. 1:52011. View Article : Google Scholar : PubMed/NCBI
8	Lee RC, Feinbaum RL and Ambros V: The Celegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
9	Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
10	Lagos-Quintana M, Rauhut R, Yalcin A, et al: Identification of tissue-specific microRNAs from mouse. Curr Biol. 12:735–739. 2002. View Article : Google Scholar : PubMed/NCBI
11	Merhautova, J, Hezova R, Poprach A, et al: miR-155 and miR-484 are associated with time to progression in metastatic renal cell carcinoma treated with sunitinib. Biomed Res Int. 2015:9419802015. View Article : Google Scholar : PubMed/NCBI
12	Ling N, Gu J, Lei Z, et al: microRNA-155 regulates cell proliferation and invasion by targeting FOXO3a in glioma. Oncol Rep. 30:2111–2118. 2013.PubMed/NCBI
13	Zhang GJ, Xiao HX, Tian HP, et al: Upregulation of microRNA-155 promotes the migration and invasion of colorectal cancer cells through the regulation of claudin-1 expression. Int J Mol Med. 31:1375–1380. 2013.PubMed/NCBI
14	Faraoni I, Antonetti FR, Cardone J and Bonmassar E: miR-155 gene, A typical multifunctional microRNA. Biochim Biophys Acta. 1792:497–505. 2009. View Article : Google Scholar : PubMed/NCBI
15	Macfarlane LA and Murphy PR: MicroRNA: Biogenesis function and role in cancer. Curr Genomics. 11:537–561. 2010. View Article : Google Scholar : PubMed/NCBI
16	Papaconstantinou IG, Manta A, Gazouli M, et al: Expression of microRNAs in patients with pancreatic cancer and its prognostic significance. Pancreas. 42:67–71. 2013. View Article : Google Scholar : PubMed/NCBI
17	Shibuya H, Iinuma H, Shimada R, Horiuchi A and Watanabe T: Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology. 79:313–320. 2010. View Article : Google Scholar : PubMed/NCBI
18	Huang Z, Huang D, Ni S, Peng Z, Sheng W and Du X: Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 127:118–126. 2010. View Article : Google Scholar : PubMed/NCBI
19	World Medical: Association: Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. http://www.wma.net/en/30publications/10policies/b3/17c.pdfAccessed. December 25–2011
20	Tsai HC and Baylin SB: Cancer epigenetics: Linking basic biology to clinical medicine. Cell Res. 21:502–517. 2011. View Article : Google Scholar : PubMed/NCBI
21	Hu YH, Cai Q and Lan QY: Expression of miR-155 in hepatocellular carcinoma and its effect on the proliferation of hepatocellular carcinoma cells. World J Gastroenterol. 19:1737–1741. 2012.
22	Song CG, Wu XY, Fu FM, et al: Correlation of miR-155 on formalin-fixed paraffin embedded tissues with invasiveness and prognosis of breast cancer. Zhonghua Wai Ke Za Zhi. 50:1011–1014. 2012.(In Chinese). PubMed/NCBI
23	Han ZB, Chen HY, Fan JW, et al: Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J Cancer Res Clin Oncol. 138:153–161. 2012. View Article : Google Scholar : PubMed/NCBI
24	Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE and Givol D: Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 54:3391–3395. 1994.PubMed/NCBI
25	Xie Q, Chen X, Lu F, et al: Aberrant expression of microRNA 155 may accelerate cell proliferation by targeting sex-determining region Y box 6 in hepatocellular carcinoma. Cancer. 118:2431–2442. 2012. View Article : Google Scholar : PubMed/NCBI
26	Yan XL, Jia YL, Chen L, et al: Hepatocellular carcinoma-associated mesenchymal stem cells promote hepatocarcinoma progression: Role of the S100A4-miR155-SOCS1-MMP9 axis. Hepatology. 57:2274–2286. 2013. View Article : Google Scholar : PubMed/NCBI
27	Shi J, Lai EC, Li N, et al: A new classification for hepatocellular carcinoma with portal vein tumor thrombus. J Hepatobiliary Pancreat Sci. 18:74–80. 2011. View Article : Google Scholar : PubMed/NCBI
28	Poon RT, Fan ST, Ng IO, et al: Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 89:500–507. 2000. View Article : Google Scholar : PubMed/NCBI
29	Sun J, Jian ZX, Ou YL, Hou BH and Qu JR: Ensured the early recurrent time and model of liver cancer after radical resection. Shi Yong Yi Xue Za Zhi. 10:1748–1750. 2011.(In Chinese).
30	Cai XR, Huang CY, Zhou LY and Zhou HH: Study on risk factors and therapeutic effect of different recurrence period after resection of primary hepatocellular carcinoma. Shi Yong Yi Xue Za Zhi. 5:560–563. 2010.(In Chinese).
31	Braconi C, Henry JC, Kogure T, Schmittgen T and Patel T: The role of microRNAs in human liver cancers. Semin Oncol. 38:752–763. 2011. View Article : Google Scholar : PubMed/NCBI
32	Shrivastava S, Steele R, Ray R and Ray RB: MicroRNAs Role in hepatitis C virus pathogenesis. Genes Dis. 2:35–45. 2015. View Article : Google Scholar : PubMed/NCBI
33	Huang YH, Lin KH, Chen HC, et al: Identification of postoperative prognostic microRNA predictors in hepatocellular carcinoma. PLoS One. 7:e371882012. View Article : Google Scholar : PubMed/NCBI